Vertex Pharmaceuticals (VRTX) Prepaid Assets (2009 - 2026)
Vertex Pharmaceuticals (VRTX) posted quarterly Prepaid Assets of $720.8 million for Q1 2026, up 12.13% year-over-year from $642.8 million in Q1 2025, and down 15.53% quarter-over-quarter from $853.3 million in Q4 2025.
Vertex Pharmaceuticals (VRTX) Prepaid Assets (2009 - 2026) Analysis & Trends
Vertex Pharmaceuticals' Prepaid Assets history runs 18 years deep, the most recent figure standing at $720.8 million for Q1 2026.
- In Q1 2026, Prepaid Assets rose 12.13% year-over-year to $720.8 million; the TTM figure through Mar 2026 stood at $720.8 million (up 12.13% YoY), while the FY2025 annual figure was $853.3 million, up 28.18% from the prior year.
- Prepaid Assets for Q1 2026 stood at $720.8 million, down from $853.3 million in the prior quarter.
- The five-year high for Prepaid Assets was $853.3 million in Q4 2025, with the low at $84.3 million in Q4 2023.
- The 5-year median for Prepaid Assets is $553.5 million (2022), against an average of $568.9 million.
- The sharpest annual moves came in 2023 and 2024: Prepaid Assets sank 84.77% in 2023, then soared 689.68% in 2024.
- Vertex Pharmaceuticals' Prepaid Assets stood at $553.5 million in 2022, then tumbled by 84.77% to $84.3 million in 2023, then jumped by 689.68% to $665.7 million in 2024, then increased by 28.18% to $853.3 million in 2025, then decreased by 15.53% to $720.8 million in 2026.
- Business Quant data shows VRTX's Prepaid Assets at $720.8 million in Q1 2026, $853.3 million in Q4 2025, and $709.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 791.90 Mn |
| Mar 31, 2026 | 720.80 Mn |
| Dec 31, 2025 | 853.30 Mn |
| Sep 30, 2025 | 709.40 Mn |
| Jun 30, 2025 | 652.30 Mn |
| Mar 31, 2025 | 642.80 Mn |
| Dec 31, 2024 | 665.70 Mn |
| Sep 30, 2024 | 449.20 Mn |
| Jun 30, 2024 | 575.40 Mn |
| Mar 31, 2024 | 511.10 Mn |
| Dec 31, 2023 | 84.30 Mn |
| Sep 30, 2023 | 540.20 Mn |
| Jun 30, 2023 | 476.90 Mn |
| Mar 31, 2023 | 468.70 Mn |
| Dec 31, 2022 | 553.50 Mn |
| Sep 30, 2022 | 726.90 Mn |
| Jun 30, 2022 | 549.50 Mn |
| Mar 31, 2022 | 491.50 Mn |
| Dec 31, 2021 | 545.80 Mn |
| Sep 30, 2021 | 457.83 Mn |